08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

Bisantrene regulatory update

Update said FDA granted Orphan Drug designation to UPI-928 to treat acute myelogenous leukemia (AML). Update said it is preparing an IND submission for the small molecule anthracene derivative. The product was approved as Zantrene...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Company News

Wyeth infectious news

The Supreme Court of Georgia ruled that Wyeth can be held liable for damages in American Home Products Corp. v. Ferrari, a case involving alleged defects in a vaccine. Damages have yet to be awarded...
01:29 , Oct 9, 2008 |  BC Extra  |  Politics & Policy

Georgia court upholds Wyeth's liability for vaccine

The Supreme Court of Georgia ruled that Wyeth (NYSE:WYE) can be held liable for damages in American Home Products Corp. v. Ferrari, a case involving alleged defects in a vaccine. In 2002, Marcelo and Carolyn...
07:00 , Jun 4, 2007 |  BioCentury  |  Strategy

Big Thinkers revisited

A decade ago, big pharma underwent the first pangs of restructuring, hoping that tried-and-true M&A would achieve faster increases in shareholder value than might have been anticipated if the individual companies had carried on alone....
07:00 , May 21, 2007 |  BioCentury  |  Finance

Ebb & Flow

Novartis has launched a new venture fund, the $200 million Novartis Option Fund , which will give the pharmaceutical company a first option to license a very early stage program at portfolio companies. "As I...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Ebb & Flow

Five executives at MedImmune (MEDI) will be receiving more than $280 million when the $15.6 billion acquisition by AstraZeneca (LSE:AZN; AZN) closes. By comparison, the biotech sector raised a total of $566 million last week,...
07:00 , Jul 17, 2006 |  BioCentury  |  Strategy

Biologic rebirth

Compared to most of big pharma, the pharmaceutical company that is now Wyeth got a number of significant biotech assets relatively early on. But apart from driving some products already in development to market, it...
07:00 , Oct 17, 2005 |  BioCentury  |  Strategy

Vaccines getting hot

For decades, infectious disease vaccines were viewed as unattractive products with low margins, small markets and liability issues. But fears of global influenza and avian flu pandemics, the SARS outbreak a few years ago and...
07:00 , May 30, 2005 |  BC Week In Review  |  Clinical News

Manhattan preclinical data

In a rat model of obesity, oleoyl-estrone (OE) led to a weight loss of 0.8% per day vs. 0.4% for dexfenfluramine or sibutramine and no weight loss with phentermine. Weight loss was maximal when OE...
08:00 , Jan 3, 2005 |  BioCentury  |  Strategy

Elan's $8B turnaround

Looking at Elan Corp. plc today, it's hard to recognize it as the same company that imploded two and a half years ago. Indeed, FDA's approval of Tysabri natalizumab for multiple sclerosis in November and...